Phase III PEACE-1 at ESMO 2026: Long-Term Overall Survival With Abiraterone in De Novo mCSPC
oncodaily - At the ESMO Congress 2026, Karim Fizazi (Lille, France) presented long-term overall survival (OS) results from the Phase III PEACE-1 trial (NCT01957436), evaluating the addition of abiraterone acetate plus prednisone […]
AI Summary: Long‑term PEACE‑1 results demonstrate that adding abiraterone to androgen‑deprivation therapy plus docetaxel significantly improves overall survival for patients with de novo metastatic castration‑sensitive prostate cancer. The survival benefit persists across key subgroups, supporting earlier intensification of systemic therapy in this high‑burden population and influencing frontline treatment algorithms.
Related Stories
Neoadjuvant GDFATHER-NEO: visugromab plus nivolumab in MIBC / 20 min
Atirmociclib reduces progression after prior CDK4/6 inhibition in endocrine‑resistant breast cancer / 5 hrs
Low pCR reported with trastuzumab‑deruxtecan in early breast cancer / 26 hrs
Merck and Moderna report positive phase‑3 melanoma vaccine results / 2 months
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 2 months
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 2 months
Perioperative advances reshape muscle‑invasive bladder cancer care / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Gene Therapy, Medicare Advantage (not listed), Infectious Disease, Medical Devices and look for the RSS link.
StackHealth Time Machine